Lung adenocarcinoma stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lung adenocarcinoma stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Lazertinib and Gefitinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-lazertinib-and-gefitinib-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:00:25 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-lazertinib-and-gefitinib-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC), specifically in cases where the cancer is locally advanced or has spread to other parts of the body (metastatic). The study is investigating two treatments: Lazertinib and Gefitinib. Both medications are taken orally in tablet form. Lazertinib is being tested under the code name YH25448A. The purpose of the study is to compare the effectiveness and safety of Lazertinib against Gefitinib as the first treatment option for patients with this type of lung cancer.

Participants in the study will receive either Lazertinib or Gefitinib. The study will monitor how long the cancer does not worsen, which is known as progression-free survival. The trial will also look at other factors such as the overall response to the treatment, how long any response lasts, and the overall survival of the participants. Additionally, the study will measure the levels of Lazertinib in the blood and cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord. Participants’ quality of life will also be assessed using questionnaires designed to evaluate the impact of the treatment on their daily lives.

This study is important for understanding which treatment might be more effective for patients with NSCLC that have specific mutations in the epidermal growth factor receptor (EGFR), which is a protein that can affect the growth of cancer cells. The trial aims to provide valuable information that could help improve treatment options for patients with this type of lung cancer.

]]>